Trade Compugen Ltd. - Ordinary Shares - CGEN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.026
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 2.357
• Open: 2.367
• 1-Year Change: 69.65%
• Day's Range: 2.327 - 2.3969

Trade Compugen Ltd. - Ordinary Shares - CGEN

About Compugen Ltd. (USA)

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Compugen Ltd. (USA) revenues increased from $2M to $6M. Net loss increased 15% to $34.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 24% to $26.7M (expense), Interest Income decrease of 49% to $894K (income).

Equity composition

Ordinary Shares NIS.01 Par, 12/10 50M auth., 33,915,545 issd. Insiders own 11.33%. IPO: 8/11/00, 5M shares @ $10 by FleetBoston Robertson Stephens. FY'00 financials are reclassified.